公司资料
BioXcel 股价、新闻与催化剂
- 股票代码:
- BTAI
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
0.07 USD (-37.11%)
收盘价
最后更新: 2026年9月4日
36.7M USD
市值
股价为何变动
目前无法获取 BTAI 的收盘价变动背景。
公司概览
业务概览
BioXcel Therapeutics is a neuroscience and immuno-oncology company focused on using artificial intelligence to identify therapeutic candidates. Its story combines data-driven discovery with development-stage biotech execution.
所在地与行业分类
BioXcel is headquartered in the United States and listed on NASDAQ. It sits in neuroscience and platform biotechnology.
商业模式特征
The company depends on clinical progress, platform validation, and the ability to turn AI-enabled discovery into real therapeutic value. Investors watch data, safety, and pipeline prioritization.
生物医药行业定位
BioXcel occupies a platform-heavy neuroscience niche within biotech. The stock is driven by whether its AI-assisted approach can support a viable pipeline.
未来催化剂
- BioXcel’s catalysts are IGALMI and the neuroscience pipeline, plus any strategic update that clarifies the company’s commercial path. The market will care about whether the product base can stabilize.
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。